PE20131398A1 - Inhibidores de oxadiazol de la produccion de leucotrienos - Google Patents

Inhibidores de oxadiazol de la produccion de leucotrienos

Info

Publication number
PE20131398A1
PE20131398A1 PE2013000629A PE2013000629A PE20131398A1 PE 20131398 A1 PE20131398 A1 PE 20131398A1 PE 2013000629 A PE2013000629 A PE 2013000629A PE 2013000629 A PE2013000629 A PE 2013000629A PE 20131398 A1 PE20131398 A1 PE 20131398A1
Authority
PE
Peru
Prior art keywords
pyridin
oxadiazol
alkyl
compounds
cyclobutil
Prior art date
Application number
PE2013000629A
Other languages
English (en)
Spanish (es)
Inventor
Alessandra Bartolozzi
Todd Bosanac
Zhidong Chen
Lombaert Stephane De
Jonathon Alan Dines
John D Huber
Weimin Liu
Pui Leng Loke
Tina Morwick
Alan Olague
Doris Riether
Heather Tye
Lifen Wu
Renee M Zindell
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44720163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131398(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20131398A1 publication Critical patent/PE20131398A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2013000629A 2010-09-23 2011-09-20 Inhibidores de oxadiazol de la produccion de leucotrienos PE20131398A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38573310P 2010-09-23 2010-09-23
US201161533349P 2011-09-12 2011-09-12

Publications (1)

Publication Number Publication Date
PE20131398A1 true PE20131398A1 (es) 2013-12-19

Family

ID=44720163

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000629A PE20131398A1 (es) 2010-09-23 2011-09-20 Inhibidores de oxadiazol de la produccion de leucotrienos

Country Status (19)

Country Link
US (1) US8575201B2 (enExample)
EP (1) EP2619197B1 (enExample)
JP (1) JP5713511B2 (enExample)
KR (1) KR20130109122A (enExample)
CN (1) CN103261193A (enExample)
AU (1) AU2011305667A1 (enExample)
BR (1) BR112013008638A2 (enExample)
CA (1) CA2812449A1 (enExample)
CL (1) CL2013000788A1 (enExample)
CO (1) CO6710902A2 (enExample)
EA (1) EA201300389A1 (enExample)
EC (1) ECSP13012548A (enExample)
IN (1) IN2013DN02555A (enExample)
MX (1) MX2013003202A (enExample)
PE (1) PE20131398A1 (enExample)
PH (1) PH12013500545A1 (enExample)
SG (1) SG188604A1 (enExample)
WO (1) WO2012040139A1 (enExample)
ZA (1) ZA201301747B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3150164B2 (ja) 1991-05-01 2001-03-26 電気化学工業株式会社 セメント混和材及びセメント組成物
EP2609092B1 (en) * 2010-08-26 2015-04-01 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
US8575201B2 (en) 2010-09-23 2013-11-05 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
US8580825B2 (en) * 2010-09-23 2013-11-12 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
US9745328B2 (en) * 2013-02-04 2017-08-29 Janssen Pharmaceutica Nv Flap modulators
ES2596248T3 (es) 2013-11-26 2017-01-05 Citrage N-Carbamoilputrescina para mejorar la síntesis de proteínas musculares

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2002356A3 (cs) 1999-08-06 2002-06-12 Janssen Pharmaceutica N. V. Deriváty 6-azauracilu inhibující interleukin-5
KR20060056377A (ko) * 2003-08-13 2006-05-24 카이론 코포레이션 Ｇｓｋ-3 억제제 및 그것의 사용
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
CA2584262A1 (en) 2004-10-18 2006-04-27 Merck & Co., Inc. Diphenyl substituted alkanes as flap inhiibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
JP2009533435A (ja) * 2006-04-11 2009-09-17 メルク エンド カムパニー インコーポレーテッド ジアリール置換アルカン
ES2376396T3 (es) 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
ATE543810T1 (de) * 2006-09-01 2012-02-15 Merck Sharp & Dohme Hemmer des 5-lipoxygenase aktivierenden proteins (flap)
US20100120784A1 (en) 2007-04-20 2010-05-13 Lachance Nicolas Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP2546232A1 (en) 2007-06-20 2013-01-16 Merck Sharp & Dohme Corp. Diphenyl Substituted Alkanes
AU2008311375A1 (en) 2007-10-10 2009-04-16 Merck Sharp & Dohme Corp. Diphenyl substituted cycloalkanes
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
ES2534199T3 (es) * 2008-10-31 2015-04-20 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
WO2010089686A1 (en) 2009-02-04 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
CN102939006A (zh) 2010-05-12 2013-02-20 范德比尔特大学 杂环砜基代谢型谷氨酸受体第4亚型(mglur4)变构增效剂，组合物，以及用以治疗神经性障碍的方法
EP2606045B1 (en) * 2010-08-16 2016-01-06 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
EP2609092B1 (en) * 2010-08-26 2015-04-01 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
US8580825B2 (en) * 2010-09-23 2013-11-12 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
US8575201B2 (en) 2010-09-23 2013-11-05 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production

Also Published As

Publication number Publication date
CN103261193A (zh) 2013-08-21
IN2013DN02555A (enExample) 2015-08-07
EP2619197A1 (en) 2013-07-31
JP2013537909A (ja) 2013-10-07
ECSP13012548A (es) 2013-06-28
PH12013500545A1 (en) 2013-05-06
EP2619197B1 (en) 2015-08-05
ZA201301747B (en) 2014-08-27
EA201300389A1 (ru) 2013-09-30
AU2011305667A1 (en) 2013-03-21
US20120295896A1 (en) 2012-11-22
CA2812449A1 (en) 2012-03-29
US8575201B2 (en) 2013-11-05
CL2013000788A1 (es) 2013-06-28
JP5713511B2 (ja) 2015-05-07
MX2013003202A (es) 2013-04-24
CO6710902A2 (es) 2013-07-15
KR20130109122A (ko) 2013-10-07
WO2012040139A1 (en) 2012-03-29
SG188604A1 (en) 2013-04-30
BR112013008638A2 (pt) 2016-06-21

Similar Documents

Publication Publication Date Title
PE20131398A1 (es) Inhibidores de oxadiazol de la produccion de leucotrienos
PE20131153A1 (es) Inhibidores de la tirosina-quinasa de bruton
PE20141005A1 (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
PE20091656A1 (es) Compuestos heterociclicos como inhibidores de la cinasa raf
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20141120A1 (es) Compuestos heterociclicos
PE20120081A1 (es) Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton
PE20141375A1 (es) Activadores de glucoquinasa
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20120321A1 (es) Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20091952A1 (es) Compuestos de tiazole y oxazole de sulfonamida de benzeno
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
CL2012001171A1 (es) Procedimiento para la preparacion del ester n-[[2-[[[4-[[[(hexiloxicarbonil)]4-amino]iminometil]fenil]amino]metil]1-alquil-1h-benzimidazol-5-il]carbonil]n-2-piridinil-etilico de beta-alanina; y uno de los compuestos intermediarios considerados.
PE20081353A1 (es) Compuestos del inhibidor de fosfoinositida 3-cinasa
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20081659A1 (es) Agonistas de gpcr
PE20131377A1 (es) Triazina-oxadiazoles
PE20142099A1 (es) Derivados de sulfonamida
PE20110906A1 (es) Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif
PE20120632A1 (es) Inhibidores de bace
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2

Legal Events

Date Code Title Description
FD Application declared void or lapsed